



sienna
CANCER DIAGNOSTICS

Sienna Cancer Diagnostics

2017 Annual General Meeting



Disclaimer

This document has been prepared by Sienna Cancer Diagnostics (Sienna) and comprises written materials/slides for a presentation concerning Sienna. The information contained in this presentation is for information purposes only and does not constitute an offer or solicitation to sell or to issue, or arrange to sell or issue, securities or other financial products.

Any such offer or solicitation will be made only by means of a confidential information memorandum and in accordance with applicable securities and other laws. The information contained in this presentation is not investment or financial product advice, is not intended to be used as the basis for making an investment decision, and no specific recommendations are intended. The presentation has been prepared without taking into account the investment objectives, financial situation or particular need of any particular person. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in the presentation.

To the maximum extent permitted by law, none of Sienna, its related companies and their respective directors, employees or advisers, nor any other person accepts any liability, including, without limitation, any liability arising out of fault. Certain statements in this presentation are forward looking statements. These forward looking statements speak only as at the date of this presentation. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements.

No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward looking statements contained in this presentation are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

The historical information in this document is, or is based upon, information that has been released to the Australian Securities Exchange (ASX). This document should be read in conjunction with SDX's other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au.

- AGM
 - Chairman's Opening
 - Business of meeting including resolutions
 - Close of AGM

- CEO Presentation

- Questions

- Tea / Coffee



sienna
CANCER DIAGNOSTICS

Annual General Meeting
Nov 10th 2017

Business of Meeting – Item 1

- Annual Report

- To table and consider the 2017 Annual Report including the Financial Report, Directors' Report, and Auditor's Report for the period 1 July 2016 to 30 June 2017

No resolution is required for this item of business

- Adoption of the Remuneration Report

- To consider and if thought fit, to pass the following non-binding Resolution

Resolution 1:

That the Company's Remuneration Report for the year ended 30 June 2017, as contained in the Directors' Report of the 2017 Annual Report, be adopted and approved

Business of Meeting – Item 3

- Re-election of Non-executive Chairman - Dr Geoffrey Cumming
 - To consider and if thought fit, to pass the following non-binding Resolution

Resolution 2:

That Dr Geoffrey Cumming, who in accordance with clause 13.3 of the Company's Constitution offers himself for re-election as a Non-executive Director, be re-elected as a Non-executive Director of the Company

Business of Meeting – Item 4

- Re-election of Non-executive Director – Mr Carl Stubbings
 - To consider and if thought fit, to pass the following non-binding Resolution

Resolution 3:

That Mr Carl Stubbings, who in accordance with clause 13.3 of the Company's Constitution offers himself for re-election as a Non-executive Director, be re-elected as a Non-executive Director of the Company

Business of Meeting – Item 5

- Re-election of Non-executive Director – Dr David J. Earp
 - To consider and if thought fit, to pass the following non-binding Resolution

Resolution 4:

That Dr David J. Earp, who in accordance with clause 13.3 of the Company's Constitution offers himself for re-election as a Non-executive Director, be re-elected as a Non-executive Director of the Company

Close of AGM



sienna
CANCER DIAGNOSTICS

CEO Presentation

High Level 12-Month Recap


- Exactly 1 year since our last AGM
- Significant milestones achieved since then...
 - FDA registration of class 1 IVD product in USA
 - CE Mark approval and IVD registration in Europe Union
 - TGA registration of class 2 IVD product in Australia
 - Raised \$1.2M in a rights issue
 - Appointed a new CEO
 - Secured distribution agreement with Biosystems Switzerland
 - Added resources in R&D Management & US Commercial Management
 - Launched the IVD test in the USA through StatLab
 - Successful IPO raising \$4.6M in new capital
 - Listed on the ASX
 - Partnered with Axlab for distribution in Denmark & Sweden

“We’ve already generated initial sales and we are still only a few months after launch. I expect significant growth over the next couple of years as the market awareness and acceptance of this new and clinically useful test increases.”

- Dr Mark Rees, VP StatLab Medical Products

IR & PR Strategy and Outcomes to Date

IR & PR Program Elements: Building a solid foundation and broadening awareness



Outcomes

- 2 x roadshows post-IPO putting us on the radar of new investors and brokers - yielding positive feedback and building support for the longer term
- Expanded and engaged audience for Sienna FNN, WE Buchan investor news, Morgans Daily Healthcare News
- IIR research report published and being used to actively engage with the market
- 8x feature media articles in key industry press
- Thought-leadership-led PR program focused on investor targeted publications and relevant industry publications beginning to drive additional coverage



Moving Forward

Overarching goal is to achieve cash flow positivity

Over the next year we want to close that gap as much as possible, through implementation of Sienna's business strategy

Continue to execute the growth strategies:

- Maximize revenue growth in the USA
 - Assist and support StatLab to penetrate the market
 - Collaborate with researchers to enable data to be presented and published
- Geographical expansion
 - Expand distribution partners in the EU
 - Identify partners to assist entry to the Asian markets
 - Expand targets to ROW
- Application expansion
 - Leverage existing product and registrations
 - Extend utility into new sample types for additional cancers
 - Combination internal R&D and external collaborations
- Pipeline expansion
 - Business Development to identify new technologies
 - In-license or acquisition of technology or company
 - Leverage existing facilities, resources, channels



sienna
CANCER DIAGNOSTICS

